Biocare Medical

What Biocare Medical does

Biocare Medical is a US-based biotechnology company founded in 1997 and headquartered in Concord, California, that develops and manufactures diagnostic instruments, antibodies, and reagents for tissue-based clinical and research pathology. Its core offerings center on immunohistochemistry (IHC), in situ hybridization (ISH), and fluorescence in situ hybridization (FISH) workflows used to detect cancer and infectious diseases in tissue samples, including a catalog of more than 300 specialized antibodies, RNA-ISH probes, and the automated NeoPATH Pro IHC staining platform. Following its November 2022 acquisition of Empire Genomics, Biocare expanded into molecular diagnostics with a portfolio exceeding one million molecular biomarkers for cancer research and precision oncology applications.

The company serves two primary end markets: clinical pathology laboratories (hospital-based and independent labs performing cancer diagnostics and treatment-decision support) and research laboratories (academic and pharmaceutical groups conducting biomarker discovery, translational research, and precision oncology). A secondary vertical includes government and military healthcare facilities using Biocare products for cancer and infectious disease detection. The company sells primarily through direct enterprise field sales to laboratories, supplemented by channel partnerships such as its March 2026 co-exclusive US distribution agreement with PreciPoint for digital slide scanning systems compatible with the NeoPATH Pro platform.

Biocare generates revenue primarily through sales of staining instruments and high-margin recurring consumables (antibodies, reagents, probes), with an additional contribution from one-time molecular diagnostics licensing. Pricing is quote-based and not publicly disclosed. From 2021 to 2026, Biocare was owned by an investor group led by Excellere Partners and GHO Capital Partners, during which it achieved double-digit annual revenue and profit growth, reaching over $90 million in 2025. In March 2026 Agilent Technologies announced a definitive agreement to acquire Biocare for $950 million in cash, completing the transaction on June 25, 2026 and integrating Biocare into Agilent's Life Sciences and Diagnostics Markets Group.

Name

Biocare Medical

Legal name

Biocare Medical LLC

Website

https://biocare.net

Company type

Private

Founded year

1997

Operating status

Acquired

Headcount range

101–250 employees

Short description

Biocare Medical develops and manufactures immunohistochemistry, in situ hybridization, and molecular diagnostic antibodies, reagents, and staining instruments for clinical pathology laboratories and cancer research institutions worldwide.

Ownership category

akta.pro rank

Product category

Clinical Pathology Diagnostics Reagents

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers) (HLAAAMAI)

akta.pro secondary industries

Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)

Keywords

• Immunohistochemistry reagents
• Tissue diagnostic antibodies
• In situ hybridization probes
• Automated IHC staining
• Molecular pathology biomarkers

Headquarters

HQ city

Concord

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Reagents and Consumables: Recurring revenue from specialized antibodies, reagents, and consumables used in immunohistochemistry and in situ hybridization testing. The portfolio of over 300 specialized antibodies drives recurring consumable revenue.
2. Staining Instruments: Sale of automated staining instruments including the NeoPATH Pro IHC staining platform. Hardware sales combined with consumables creates land-and-expand revenue opportunity.
3. Molecular Diagnostics Solutions: Molecular biomarker products and solutions for cancer research and diagnostics, expanded through Empire Genomics acquisition to over 1 million biomarkers.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

Biocare Medical develops and manufactures immunohistochemistry (IHC), in situ hybridization (ISH), and fluorescence in situ hybridization (FISH) solutions for clinical and research pathology. The product portfolio includes over 300 specialized antibodies, RNA-ISH probes, automated staining instruments such as the NeoPATH Pro platform, and a molecular biomarker library of more than 1 million biomarkers acquired through Empire Genomics. These products are used by clinical pathology laboratories, research institutions, and government healthcare facilities for cancer diagnostics, infectious disease detection, and translational research.

Product overview

Biocare Medical is a global leader in clinical and research pathology solutions, offering an integrated portfolio of immunohistochemistry, in situ hybridization (ISH), and fluorescence in situ hybridization (FISH) products. The company's core offerings include over 300 specialized antibodies, RNA-ISH probes, staining instruments, and reagents for detecting cancer and infectious diseases. The NeoPATH Pro IHC staining platform provides automated staining capabilities and integrates with digital pathology solutions from partners like PreciPoint. Following the 2022 acquisition of Empire Genomics, the company expanded its molecular biomarker portfolio to over 1 million biomarkers, enhancing its capabilities in molecular diagnostics and biomarker analysis for precision oncology applications.

Differentiator

Problem solved

Functional benefit

Products and services

• Immunohistochemistry (IHC) Solutions Comprehensive IHC product line including specialized antibodies, reagents, and instruments for detecting cancer and infectious diseases in tissue samples, supported by a portfolio of over 300 specialized antibodies. Targeted at clinical pathology laboratories, hospital systems, and research institutions.
• In Situ Hybridization (ISH) Solutions RNA-ISH probes and related reagents used to detect specific RNA sequences within tissue samples for molecular pathology diagnostics and translational research. Used by clinical and research pathology laboratories.
• Fluorescence In Situ Hybridization (FISH) Solutions FISH probes and assays for detecting chromosomal abnormalities and genetic alterations in tissue samples, applied in cancer diagnostics and cytogenetic research. Targeted at clinical cytogenetics and pathology laboratories.
• NeoPATH Pro IHC Staining Platform Automated IHC staining instrument designed to standardize and accelerate immunohistochemistry and in situ hybridization workflows. Compatible with PreciPoint's digital slide scanning systems for integrated digital pathology solutions. Sold to clinical pathology laboratories.
• Molecular Biomarkers Portfolio

Quantifiable outcome

• Double-digit annual revenue and profit growth since 2021
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature5 records

Partnerships

Four partnerships are on record, tiered core and strategic.

• ProteintechcoreStrategic or Co-development Partner · 23 March 2026Strategic collaboration and co-development agreement to advance next-generation antibody solutions for modern pathology workflows. Combines Proteintech's antibody discovery and protein engineering capabilities with Biocare's diagnostic assay and immunohistochemistry expertise. Aims to accelerate development of high-performance antibody reagents for tissue-based diagnostics, translational research, and precision oncology applications, including antibody-drug conjugates and companion diagnostics. Addresses antibody reproducibility and assay standardization challenges in digital pathology.
• PreciPoint GmbHcoreChannel Partner/ Reseller/ Distributor · 18 March 2026Co-exclusive distribution partnership to distribute PreciPoint's digital slide scanning systems, imaging solutions, and software for immunohistochemistry and in situ hybridization applications in the United States. Expands access to cost-effective digital pathology tools for laboratories seeking high-quality case scanning, digital quality control, and workflow visualization without high-throughput system complexity. Compatible with Biocare's NeoPATH Pro IHC staining platform. Currently available as Research Use Only in the United States.
• Hamamatsu CorporationstrategicStrategic or Co-development Partner · 30 October 2025Strategic collaboration to deliver integrated spatial biology solutions combining Biocare's staining platforms with Hamamatsu's MoxiePlex imaging system. Aims to enhance research capabilities in cancer, immuno-oncology, and translational science for research institutions and biotech companies.
• Empire GenomicsstrategicStrategic or Co-development Partner · 22 November 2022Acquired company specializing in molecular biomarkers for cancer research and diagnostics. The acquisition expanded Biocare's molecular portfolio to over 1 million biomarkers and enhanced biomarker development and automation integration capabilities for accelerating cancer research and diagnostics.

Scale indicators6 records

Recent moves7 records

Expansion highlights4 records

Market position

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/biocarem
• Facebookfacebook.com/biocaremedical
• LinkedInlinkedin.com/company/biocare-medical

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biocare Medical